JPRN-UMIN000012834CompletedPhase 2
Phase II study of intraperitoneal paclitaxel combined with S-1 plus oxaliplatin for advanced gastric cancer with peritoneal metastasis - Phase II study of SOX+IP PTX
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- The University of Tokyo
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions.
Investigators
Similar Trials
Completed
Phase 2
Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000023000agoya University50
Completed
Phase 2
Phase II study of intraperitoneal paclitaxel combined with S-1 plus oxaliplatin as second-line chemotherapy for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000012836The University of Tokyo50
Completed
Phase 1
Exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for gastric cancer patients with peritoneal metastasis and inadequate oral intakegastric cancer with peritoneal metastasisJPRN-UMIN000019206The University of Tokyo34
Completed
Phase 1
Phase I study of weekly intraperitoneal paclitaxel combined with oxaliplatin plus S-1 for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000004978The University of Tokyo Hospital9
Recruiting
Phase 2
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric CancerAdvanced or recurrent gastric cancer previously treated with S-1JPRN-UMIN000008632Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine35